103 related articles for article (PubMed ID: 6498846)
1. A diagnostic-prognostic test for bladder cancer using a monoclonal antibody-based enzyme-linked immunoassay for detection of urinary fibrin(ogen) degradation products.
McCabe RP; Lamm DL; Haspel MV; Pomato N; Smith KO; Thompson E; Hanna MG
Cancer Res; 1984 Dec; 44(12 Pt 1):5886-93. PubMed ID: 6498846
[TBL] [Abstract][Full Text] [Related]
2. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive diagnosis of bladder carcinoma by enzyme-linked immunosorbent assay detection of CD44 isoforms in exfoliated urothelia.
Woodman AC; Goodison S; Drake M; Noble J; Tarin D
Clin Cancer Res; 2000 Jun; 6(6):2381-92. PubMed ID: 10873090
[TBL] [Abstract][Full Text] [Related]
4. [Clinical evaluation of urinary NMP22 (nuclear matrix protein 22) bladder chek in the detection of patients with bladder cancer].
Kitsukawa S; Yamamoto Y; Hosoda S; Otsuru N; Matsumoto T; Matsumoto T; Aizawa T; Noda K; Ito T
Hinyokika Kiyo; 2006 Mar; 52(3):167-72. PubMed ID: 16617867
[TBL] [Abstract][Full Text] [Related]
5. Comparison of screening methods in the detection of bladder cancer.
Ramakumar S; Bhuiyan J; Besse JA; Roberts SG; Wollan PC; Blute ML; O'Kane DJ
J Urol; 1999 Feb; 161(2):388-94. PubMed ID: 9915409
[TBL] [Abstract][Full Text] [Related]
6. Utility of slot-blot-ELISA as a new, fast, and sensitive immunoassay for detection of carcinoembryonic antigen in the urine samples of patients with various gastrointestinal malignancies.
El-Masry S; El-Sayed IH; Lotfy M; Mahmoud L; El-Naggar M
J Immunoassay Immunochem; 2007; 28(2):91-105. PubMed ID: 17424828
[TBL] [Abstract][Full Text] [Related]
7. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison.
Hautmann S; Toma M; Lorenzo Gomez MF; Friedrich MG; Jaekel T; Michl U; Schroeder GL; Huland H; Juenemann KP; Lokeshwar VB
Eur Urol; 2004 Oct; 46(4):466-71. PubMed ID: 15363562
[TBL] [Abstract][Full Text] [Related]
8. An office-based immunodiagnostic assay for detecting urinary nuclear matrix protein 52 in patients with bladder cancer.
Attallah AM; Sakr HA; Ismail H; Abdel-Hady el-SK; El-Dosoky I
BJU Int; 2005 Aug; 96(3):334-9. PubMed ID: 16042726
[TBL] [Abstract][Full Text] [Related]
9. A dipstick, dot-ELISA assay for the rapid and early detection of bladder cancer.
Attallah AM; Helmi H; el-Helali E; el-Mohamadi H
Cancer Detect Prev; 1991; 15(6):495-9. PubMed ID: 1723657
[TBL] [Abstract][Full Text] [Related]
10. Hemoglobinuria detection in 195 urology patients.
Houston CW; Jin GF; Baron S; Warren MM
Cancer Detect Prev; 1988; 13(2):137-44. PubMed ID: 3242823
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF
Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234
[TBL] [Abstract][Full Text] [Related]
12. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
Słojewski M
Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
[TBL] [Abstract][Full Text] [Related]
13. Urinary calreticulin in the diagnosis of bladder urothelial carcinoma.
Kageyama S; Isono T; Matsuda S; Ushio Y; Satomura S; Terai A; Arai Y; Kawakita M; Okada Y; Yoshiki T
Int J Urol; 2009 May; 16(5):481-6. PubMed ID: 19389084
[TBL] [Abstract][Full Text] [Related]
14. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
[TBL] [Abstract][Full Text] [Related]
15. Specific identification of urinary fibrinogen, fibrinogen degradation products, and cross-linked fibrin degradation products in renal diseases and after renal allotransplantation.
Scott WL; Francis CW; Knutson DW; Marder VJ
J Lab Clin Med; 1986 Jun; 107(6):534-43. PubMed ID: 3519810
[TBL] [Abstract][Full Text] [Related]
16. Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer.
Pham HT; Block NL; Lokeshwar VB
Cancer Res; 1997 Feb; 57(4):778-83. PubMed ID: 9044860
[TBL] [Abstract][Full Text] [Related]
17. Use of the novel marker BLCA-1 for the detection of bladder cancer.
Myers-Irvin JM; Landsittel D; Getzenberg RH
J Urol; 2005 Jul; 174(1):64-8. PubMed ID: 15947579
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C
J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
[TBL] [Abstract][Full Text] [Related]
19. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer.
Durkan GC; Nutt JE; Marsh C; Rajjayabun PH; Robinson MC; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2003 Jul; 9(7):2576-82. PubMed ID: 12855633
[TBL] [Abstract][Full Text] [Related]
20. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
